DKK1 and intrahepatic cholangiocarcinoma: Preclinical studies have demonstrated that DKK1-targeting agents, such as the monoclonal antibody DKN-01, exhibit promising antitumor effects in Wnt-driven malignancies, including esophageal, intrahepatic cholangiocarcinoma, and gallbladder cancer [38].